A batch of drugs stopped supplying in Guizhou involving Wyeth Pharmaceuticals, Southwest Pharmaceuticals, Suzhou Second Leaf and so on.

On September 14th, the Office of the Leading Group for The Central Procurement of Drugs in Guizhou Province issued a notice that some enterprises had been unable to guarantee the supply of drugs due to the transformation of production lines, production stoppages and other reasons, submitted an application for the cancellation of the qualification of their products in the centralized procurement of drugs in the province (hanging net), and promised that from the date of cancellation, the enterprise shall not participate in the centralized procurement of drugs in Guizhou Province for two years.
announcement, from September 14, 2020, the drug in the x image below will be disqualified from winning the bid (hanging net).
at the same time, Guizhou Province requires medical institutions to cancel the winning bid (hanging net) qualified drugs, according to clinical needs to choose similar products procurement and use.
A total of 22 drugs on this list have been disqualified from winning the bid, including injections of amber, cephalosporinecapsules, raw pulse drinks, yew alcohol injections, including commonly used large varieties, involving Wyeth Pharmaceuticals, Taiji Group Chongqing Chinese Medicine Co., Ltd., Southwest Pharmaceuticals, Suzhou Diye Pharmaceutical Co., Ltd. and other well-known pharmaceutical companies.
.